Waldenstrom Macroglobulinemia is a malignancy that begins in B cells. Multiple myeloma and non-Hodgkin lymphoma are two more forms of cancer whose cancer cells resemble those of WM. Non-Hodgkin lymphoma is a cancer of lymphocytes, whereas multiple myeloma is a malignancy of plasma cells. Lymphoplasmacytoid cells are WM cells with characteristics of both plasma cells and lymphocytes.
WM cells produce a form of antibody known as a macroglobulin (immunoglobulin M, or IgM) in high quantities. Since each antibody (protein) produced by WM cells is identical, it is known as a monoclonal protein, or M protein. The accumulation of this M protein can cause numerous WM symptoms in the body, including excessive bleeding, eye problems, and nerve system issues.
The WM cells proliferate mostly in the bone marrow, where they can outcompete the normal cells that produce the other blood cell types. This might result in low red blood cell counts (anaemia), which can cause fatigue and weakness. It can also lead to low white blood cell counts, making it difficult for the body to fight infection. Platelet counts in the blood might also decrease, resulting in greater bleeding and bruising.
Epidemiology
Lymphoplasmacytic lymphoma is a neoplasm with an incidence of three to four cases per million persons each year. It accounts for around 2% of hematologic malignancies. In the US, 1000-1500 cases of WM are diagnosed annually. This disease that primarily affects elderly men and women in their seventh and eighth decades of life.
The majority of patients diagnosed with this disease live 7 to 8 years after diagnosis. In uncommon instances, lymphoplasmacytic lymphoma might mutate into an immunoblastic variety or into other high-grade lymphomas.
Anatomy
Pathophysiology
It is believed that the malignant cells in Waldenstrom Macroglobulinemia derive from cells at a late stage of B-cell development. Upon somatic hypermutation in the germinal center and before to plasma cell terminal differentiation, these cells derive from a B-cell arrest.
The clinical manifestations of lymphoplasmacytic lymphoma are tiny lymphocyte infiltration of the bone marrow and IgM monoclonal gammopathy. Blood flow sluggishness and hyperviscosity are associated with visual and neurological problems.
Bleeding in lymphoplasmacytic lymphoma is caused by the binding of IgM to clot factors. In Waldenstrom macroglobulinemia patients, cryoglobulinemia causes Raynaud’s phenomenon and cold urticaria.
Etiology
Lymphoplasmacytic lymphoma has a poorly characterized pathogenesis. However, it has been established that the condition is associated with hepatitis C and other autoimmune problems. One method of successfully treating patients is using antiviral medications to treat hepatitis C and Waldenstrom Macroglobulinemia.
Genetical predisposition accounts for 20% of WM cases. These patients typically develop the condition at a younger age and exhibit a higher degree of bone marrow involvement. Many research organizations are interested in the prognostic significance of genetic susceptibility in Waldenstrom Macroglobulinemia.
Genetics
Prognostic Factors
Patients with lymphoplasmacytic lymphoma have a median survival time of roughly five years. About forty percent of patients live for at least ten years. Typically, advanced age-related comorbidities account for a greater proportion of deaths than WM.
Each of the five factors in the International Prognostic Scoring System for WM receives 1 point, except for age, which receives 2 points.
The parameters which indicate a worse prognosis are stated below:
Age >65
Hemoglobin 11.5 g/dl
Platelet count 100 x10/L
Serum B microglobulin >3 mg/
Serum monoclonal protein > 70 g/L
Low risk (score 1), intermediate risk (score 2), and high risk (score 3) are determined by the score at the commencement of treatment, with 5-year survival rates of 87.68 and 36.0%, respectively.
Increased immunoblasts or transformed cells and 6q deletion are regarded as separate negative factors. A negative outcome is connected with the lack of a MYD88 L265P mutation. Poor prognosis is associated with lymphoplasmacytic lymphoma, which can evolve into diffuse large B-cell lymphoma if left untreated.
every 4 weeks or 0.1 mg/kg SUBQ per day for 5 days every month in combination with rituximab
Dose Adjustments
CrCl 10 to 50 ml/minute: administer 75% of dose
CrCl <10 ml/minute: administer 50% of dose
CAPD: administer 50% of dose
CrCl > 60 ml/minute: no dosage adjustment necessary
CrCl < 60 ml/minute: use is not recommended
Hemodialysis: use is not recommended
eGFR <50 ml/minute: use not recommended
For moderate to severe hepatic impairment: use is not recommended
No dose adjustment recommended for renal impairment.
Reduce the dose to 140 mg OD for mild hepatic impairment.
Reduce the dose to 70 mg OD for moderate hepatic impairment.
Avoid use for severe hepatic impairment.
Waldenstrom Macroglobulinemia is a malignancy that begins in B cells. Multiple myeloma and non-Hodgkin lymphoma are two more forms of cancer whose cancer cells resemble those of WM. Non-Hodgkin lymphoma is a cancer of lymphocytes, whereas multiple myeloma is a malignancy of plasma cells. Lymphoplasmacytoid cells are WM cells with characteristics of both plasma cells and lymphocytes.
WM cells produce a form of antibody known as a macroglobulin (immunoglobulin M, or IgM) in high quantities. Since each antibody (protein) produced by WM cells is identical, it is known as a monoclonal protein, or M protein. The accumulation of this M protein can cause numerous WM symptoms in the body, including excessive bleeding, eye problems, and nerve system issues.
The WM cells proliferate mostly in the bone marrow, where they can outcompete the normal cells that produce the other blood cell types. This might result in low red blood cell counts (anaemia), which can cause fatigue and weakness. It can also lead to low white blood cell counts, making it difficult for the body to fight infection. Platelet counts in the blood might also decrease, resulting in greater bleeding and bruising.
Lymphoplasmacytic lymphoma is a neoplasm with an incidence of three to four cases per million persons each year. It accounts for around 2% of hematologic malignancies. In the US, 1000-1500 cases of WM are diagnosed annually. This disease that primarily affects elderly men and women in their seventh and eighth decades of life.
The majority of patients diagnosed with this disease live 7 to 8 years after diagnosis. In uncommon instances, lymphoplasmacytic lymphoma might mutate into an immunoblastic variety or into other high-grade lymphomas.
It is believed that the malignant cells in Waldenstrom Macroglobulinemia derive from cells at a late stage of B-cell development. Upon somatic hypermutation in the germinal center and before to plasma cell terminal differentiation, these cells derive from a B-cell arrest.
The clinical manifestations of lymphoplasmacytic lymphoma are tiny lymphocyte infiltration of the bone marrow and IgM monoclonal gammopathy. Blood flow sluggishness and hyperviscosity are associated with visual and neurological problems.
Bleeding in lymphoplasmacytic lymphoma is caused by the binding of IgM to clot factors. In Waldenstrom macroglobulinemia patients, cryoglobulinemia causes Raynaud’s phenomenon and cold urticaria.
Lymphoplasmacytic lymphoma has a poorly characterized pathogenesis. However, it has been established that the condition is associated with hepatitis C and other autoimmune problems. One method of successfully treating patients is using antiviral medications to treat hepatitis C and Waldenstrom Macroglobulinemia.
Genetical predisposition accounts for 20% of WM cases. These patients typically develop the condition at a younger age and exhibit a higher degree of bone marrow involvement. Many research organizations are interested in the prognostic significance of genetic susceptibility in Waldenstrom Macroglobulinemia.
Patients with lymphoplasmacytic lymphoma have a median survival time of roughly five years. About forty percent of patients live for at least ten years. Typically, advanced age-related comorbidities account for a greater proportion of deaths than WM.
Each of the five factors in the International Prognostic Scoring System for WM receives 1 point, except for age, which receives 2 points.
The parameters which indicate a worse prognosis are stated below:
Age >65
Hemoglobin 11.5 g/dl
Platelet count 100 x10/L
Serum B microglobulin >3 mg/
Serum monoclonal protein > 70 g/L
Low risk (score 1), intermediate risk (score 2), and high risk (score 3) are determined by the score at the commencement of treatment, with 5-year survival rates of 87.68 and 36.0%, respectively.
Increased immunoblasts or transformed cells and 6q deletion are regarded as separate negative factors. A negative outcome is connected with the lack of a MYD88 L265P mutation. Poor prognosis is associated with lymphoplasmacytic lymphoma, which can evolve into diffuse large B-cell lymphoma if left untreated.
every 4 weeks or 0.1 mg/kg SUBQ per day for 5 days every month in combination with rituximab
Dose Adjustments
CrCl 10 to 50 ml/minute: administer 75% of dose
CrCl <10 ml/minute: administer 50% of dose
CAPD: administer 50% of dose
CrCl > 60 ml/minute: no dosage adjustment necessary
CrCl < 60 ml/minute: use is not recommended
Hemodialysis: use is not recommended
eGFR <50 ml/minute: use not recommended
For moderate to severe hepatic impairment: use is not recommended
No dose adjustment recommended for renal impairment.
Reduce the dose to 140 mg OD for mild hepatic impairment.
Reduce the dose to 70 mg OD for moderate hepatic impairment.
Avoid use for severe hepatic impairment.
Waldenstrom Macroglobulinemia is a malignancy that begins in B cells. Multiple myeloma and non-Hodgkin lymphoma are two more forms of cancer whose cancer cells resemble those of WM. Non-Hodgkin lymphoma is a cancer of lymphocytes, whereas multiple myeloma is a malignancy of plasma cells. Lymphoplasmacytoid cells are WM cells with characteristics of both plasma cells and lymphocytes.
WM cells produce a form of antibody known as a macroglobulin (immunoglobulin M, or IgM) in high quantities. Since each antibody (protein) produced by WM cells is identical, it is known as a monoclonal protein, or M protein. The accumulation of this M protein can cause numerous WM symptoms in the body, including excessive bleeding, eye problems, and nerve system issues.
The WM cells proliferate mostly in the bone marrow, where they can outcompete the normal cells that produce the other blood cell types. This might result in low red blood cell counts (anaemia), which can cause fatigue and weakness. It can also lead to low white blood cell counts, making it difficult for the body to fight infection. Platelet counts in the blood might also decrease, resulting in greater bleeding and bruising.
Lymphoplasmacytic lymphoma is a neoplasm with an incidence of three to four cases per million persons each year. It accounts for around 2% of hematologic malignancies. In the US, 1000-1500 cases of WM are diagnosed annually. This disease that primarily affects elderly men and women in their seventh and eighth decades of life.
The majority of patients diagnosed with this disease live 7 to 8 years after diagnosis. In uncommon instances, lymphoplasmacytic lymphoma might mutate into an immunoblastic variety or into other high-grade lymphomas.
It is believed that the malignant cells in Waldenstrom Macroglobulinemia derive from cells at a late stage of B-cell development. Upon somatic hypermutation in the germinal center and before to plasma cell terminal differentiation, these cells derive from a B-cell arrest.
The clinical manifestations of lymphoplasmacytic lymphoma are tiny lymphocyte infiltration of the bone marrow and IgM monoclonal gammopathy. Blood flow sluggishness and hyperviscosity are associated with visual and neurological problems.
Bleeding in lymphoplasmacytic lymphoma is caused by the binding of IgM to clot factors. In Waldenstrom macroglobulinemia patients, cryoglobulinemia causes Raynaud’s phenomenon and cold urticaria.
Lymphoplasmacytic lymphoma has a poorly characterized pathogenesis. However, it has been established that the condition is associated with hepatitis C and other autoimmune problems. One method of successfully treating patients is using antiviral medications to treat hepatitis C and Waldenstrom Macroglobulinemia.
Genetical predisposition accounts for 20% of WM cases. These patients typically develop the condition at a younger age and exhibit a higher degree of bone marrow involvement. Many research organizations are interested in the prognostic significance of genetic susceptibility in Waldenstrom Macroglobulinemia.
Patients with lymphoplasmacytic lymphoma have a median survival time of roughly five years. About forty percent of patients live for at least ten years. Typically, advanced age-related comorbidities account for a greater proportion of deaths than WM.
Each of the five factors in the International Prognostic Scoring System for WM receives 1 point, except for age, which receives 2 points.
The parameters which indicate a worse prognosis are stated below:
Age >65
Hemoglobin 11.5 g/dl
Platelet count 100 x10/L
Serum B microglobulin >3 mg/
Serum monoclonal protein > 70 g/L
Low risk (score 1), intermediate risk (score 2), and high risk (score 3) are determined by the score at the commencement of treatment, with 5-year survival rates of 87.68 and 36.0%, respectively.
Increased immunoblasts or transformed cells and 6q deletion are regarded as separate negative factors. A negative outcome is connected with the lack of a MYD88 L265P mutation. Poor prognosis is associated with lymphoplasmacytic lymphoma, which can evolve into diffuse large B-cell lymphoma if left untreated.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
